Login to Your Account



Still Seeking to Move Beyond HIV, HCV

Gilead Boosts Cancer Pipeline in $510M YM BioSciences Deal

By Marie Powers
Staff Writer

Thursday, December 13, 2012

One day after disclosing a 2-for-1 stock split, Gilead Sciences Inc. surprised the biotech world with a deal to acquire Canadian firm YM BioSciences Inc. in a transaction Gilead valued at $510 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription